Human papillomavirus vaccine uptake among adolescent survivors of hematopoietic stem cell transplant
Journal of Cancer Survivorship · 2024
DOI: 10.1007/s11764-024-01709-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cancer Survivorship, 2024. Verfasst von Aimee Morrison und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric and Adolescent Gynecology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Papillomavirus Vaccines, Papillomavirus Infections, Vaccination. Die Arbeit nennt 56 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: To characterize the rate of human papillomavirus (HPV) vaccine uptake among adolescents after hematopoietic stem cell transplant (HSCT). METHODS: This retrospective study evaluated the vaccine history of adolescent patients ≥ 11 years of age who underwent either auto- or allo-HSCT between 2015 and 2022 at a tertiary care medical center. Logistic regression was used to examine bivariate associations between HPV vaccine uptake and covariates including demographic factors, indication for and type of HSCT, receipt of HPV vaccine prior to transplant, and receipt of other vaccines after transplant. RESULTS: Among 119 (n = 53 female; n = 66 male) eligible patients, 66 (55.5%) received at least one dose of the HPV vaccine after HSCT. Among those who initiated vaccination, 45/66 (68.2%) completed two or more doses. Of the 69 patients who were eligible to receive the vaccine prior to HSCT, 19/36 (52%) were vaccinated both before and after HSCT, compared to 14/33 (42%) who did not receive the vaccine before HSCT but chose to be vaccinated after HSCT. No statistically significant difference was identified between those who did and did not initiate HPV vaccination after HSCT among covariates examined. CONCLUSIONS: Rate of HPV vaccine uptake after HSCT was lower than the rate of other recommended vaccines. Receiving HPV vaccine prior to HSCT was not associated with HPV re-uptake after HSCT. IMPLICATIONS FOR CANCER SURVIVORS: HPV vaccination continues to be suboptimal in HSCT survivorship and should be a targeted goal for improvement in preventing secondary malignancy in this high-risk population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pediatric and Adolescent Gynecology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.
- Division of Hematopoietic Stem Cell Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA. kasiani.myers@cchmc.org.
Zitieren
APA
Morrison, A., Myers, K., & Streich-Tilles, T. (2024). Human papillomavirus vaccine uptake among adolescent survivors of hematopoietic stem cell transplant. Journal of Cancer Survivorship. https://doi.org/10.1007/s11764-024-01709-w
Vancouver
Morrison A, Myers K, Streich-Tilles T. Human papillomavirus vaccine uptake among adolescent survivors of hematopoietic stem cell transplant. Journal of Cancer Survivorship. 2024. doi:10.1007/s11764-024-01709-w
BibTeX
@article{Morrison2024,
author = {Morrison, Aimee and Myers, Kasiani and Streich-Tilles, Tara},
title = {Human papillomavirus vaccine uptake among adolescent survivors of hematopoietic stem cell transplant},
journal = {Journal of Cancer Survivorship},
year = {2024},
doi = {10.1007/s11764-024-01709-w}
}
EUVIMED